PubMed=15274292
Li Q., Verschraegen C.F., Mendoza J.T., Hassan R.
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Anticancer Res. 24:1327-1335(2004)

PubMed=22426987; DOI=10.3892/or.2012.1725; PMCID=PMC6310027
Kalra N., Ashai A., Xi L.-Q., Zhang J.-L., Avital I., Raffeld M., Hassan R.
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Oncol. Rep. 27:1794-1800(2012)

PubMed=22552293; DOI=10.1158/0008-5472.CAN-11-3481; PMCID=PMC3389268
Jube S., Rivera Z.S., Bianchi M.E., Powers A., Wang E., Pagano I., Pass H.I., Gaudino G., Carbone M., Yang H.-N.
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.
Cancer Res. 72:3290-3301(2012)

PubMed=22893632; DOI=10.1158/1078-0432.CCR-12-0628; PMCID=PMC3463742
Rivera Z.S., Ferrone S., Wang X.-H., Jube S., Yang H.-N., Pass H.I., Kanodia S., Gaudino G., Carbone M.
CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Clin. Cancer Res. 18:5352-5363(2012)